Caracterización y variabilidad de los informes de evaluación de medicamentos en la página web del grupo GENESIS de la SEFH

Ortega, Ana; Latorre, F. Puigventós; Santos-Ramos, Bernardo; Hernanz, Beatriz Calderón; Boltó, M. Vilanova

doi:10.1016/j.farma.2010.07.006

Cited by 6 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be because of the tendency in Spain to standardize assessment methodologies, as encouraged by the Group for Innovation, Assessment, Standardization and Research in the Selection of Drugs 17. This means that different hospitals and PTCs may use similar selection systems and procedures.…”

Section: Discussionmentioning

confidence: 99%

Drug assessment by a Pharmacy and Therapeutics committee: from drug selection criteria to use in clinical practice

Blázquez¹,

Calvo-Pita²,

Carbajales-Álvarez³

et al. 2014

TCRM

View full text Add to dashboard Cite

BackgroundIn Spain, hospital medicines are assessed and selected by local Pharmacy and Therapeutics committees (PTCs). Of all the drugs assessed, cancer drugs are particularly important because of their budgetary impact and the sometimes arguable added value with respect to existing alternatives. This study analyzed the PTC drug selection process and the main objective was to evaluate the degree of compliance of prescriptions for oncology drugs with their criteria for use.MethodsThis was a retrospective observational study (May 2007 to April 2010) of PTC-assessed drugs. The variables measured to describe the committee’s activity were number of drugs assessed per year and number of drugs included in any of these settings: without restrictions, with criteria for use, and not included in formulary. These drugs were also analyzed by therapeutic group. To assess the degree of compliance of prescriptions, a score was calculated to determine whether prescriptions for bevacizumab, cetuximab, trastuzumab, and bortezomib were issued in accordance with PTC drug use criteria.ResultsThe PTC received requests for inclusion of 40 drugs, of which 32 were included in the hospital formulary (80.0%). Criteria for use were established for 28 (87.5%) of the drugs included. In total, 293 patients were treated with the four cancer drugs in eight different therapeutic indications. The average prescription compliance scores were as follows: bevacizumab, 83% for metastatic colorectal cancer, 100% for metastatic breast cancer, and 82.3% for non-small-cell lung cancer; cetuximab, 62.0% for colorectal cancer and 50% for head and neck cancer; trastuzumab, 95.1% for early breast cancer and 82.4% for metastatic breast cancer; and bortezomib, 63.7% for multiple myeloma.ConclusionThe degree of compliance with criteria for use of cancer drugs was reasonably high. PTC functions need to be changed so that they can carry out more innovative tasks, such as monitoring conditions for drug use.

show abstract

Section: Discussionmentioning

confidence: 99%

Drug assessment by a Pharmacy and Therapeutics committee: from drug selection criteria to use in clinical practice

Blázquez¹,

Calvo-Pita²,

Carbajales-Álvarez³

et al. 2014

TCRM

View full text Add to dashboard Cite

show abstract

“…Residents at the home between August 2012, when the new model was implemented, and December 2016 were included. This period of 53 months is in line with the recommended horizon of 3 to 4 years for budget impact analyses12 and was also considered necessary in order to accurately reflect mean annual activity. All healthcare interventions were aligned with the pre-defined protocol prepared by the hospital’s pharmacotherapy committee and approved by the hospital management team.…”

Section: Methodsmentioning

confidence: 98%

Budget impact analysis of two pharmaceutical management models in relation to the administration of intravenous anti-infective therapy in a Spanish nursing home

Martínez-Casal¹,

Rodriguez-Sánchez²,

Otero-Espinar

2019

Eur J Hosp Pharm

View full text Add to dashboard Cite

ObjectiveTo perform a cost-effectiveness and budget impact analysis from the perspective of the Spanish public healthcare system (SHS) to compare the number of overnight hospital stays avoided under a community and a hospital pharmacy model due to the administration of intravenous anti-infective therapy (IVAT) at a nursing home with 145 beds.MethodsAnalytical, observational, retrospective cohort study of a nursing home in Galicia (north-west Spain) that switched from a community to a hospital pharmaceutical management model. We compared the number of IVAT administrations, the number of hospital transfers and stays avoided, and mean annual costs avoided by the SHS before and after the switch. Costs were calculated using official SHS rates.ResultsThe switch from the community to the hospital pharmacy model resulted in 2.8 more IVAT administrations (95% CI, 2.71 to 2.88) and 20.79 fewer overnight hospital stays (95% CI, 20.07 to 21.51) per 100 nursing home beds a month (p<0.001). The net monthly avoided cost for the SHS was 9971.52 €2019. The budget impact analysis showed that implementation of this model throughout Galicia and Spain would respectively avoid costs of 13.78 and 221.21 million €2019 a year.ConclusionsHospital pharmacy models can contribute to a better optimisation of public healthcare resources and help improve the sustainability of the SHS.

show abstract

“…In order for new drugs to be included, they must follow the GINF guideline. In addition, GENESIS contributes to training and research in drug assessment and selection [9].…”

Section: Introductionmentioning

confidence: 99%

Differences in cancer drug assessment between Spain and the United Kingdom

Blázquez

Dickson

Fraga-Fuentes

et al. 2015

European Journal of Cancer

View full text Add to dashboard Cite

Caracterización y variabilidad de los informes de evaluación de medicamentos en la página web del grupo GENESIS de la SEFH

Abstract: The work carried out by the GENESIS group has enabled Spanish hospitals to share their drug assessment reports and making them more complete, although there are still some aspects that can be improved.

Cited by 6 publications

References 20 publications

Drug assessment by a Pharmacy and Therapeutics committee: from drug selection criteria to use in clinical practice

Drug assessment by a Pharmacy and Therapeutics committee: from drug selection criteria to use in clinical practice

Budget impact analysis of two pharmaceutical management models in relation to the administration of intravenous anti-infective therapy in a Spanish nursing home

Differences in cancer drug assessment between Spain and the United Kingdom

Contact Info

Product

Resources

About